Profil
Elisabeth Whiting joined AnorMED in February 2001 and is responsible for the company's corporate strategic planning as well as all aspects of internal and external communications and investor relations.
Ms. Whiting has over 10 years of management experience in the biotechnology field including scientific research, financial and scientific communications and business development.
Prior to joining AnorMED, Ms. Whiting was Director, Investor Relations and Corporate Communications at Stressgen Biotechnologies Inc. Ms. Whiting holds a Masters of Science degree from the University of Ottawa.
Anciens postes connus de Elisabeth Whiting
| Sociétés | Poste | Fin |
|---|---|---|
AnorMED, Inc.
 AnorMED, Inc. Pharmaceuticals: MajorHealth Technology AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. | Public Communications Contact | 09/11/2006 |
Formation de Elisabeth Whiting
| University of Ottawa | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
AnorMED, Inc.
AnorMED, Inc. Pharmaceuticals: MajorHealth Technology AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. | Health Technology |
